Afamelanotide mastery course
Unit 11 of 12
Regulatory status and access
Afamelanotide is approved by both the EMA and the FDA, but only for preventing phototoxicity in adults with EPP. This u…
Approved for EPP, and what that does and does not cover
Afamelanotide is approved by both the EMA and the FDA, but only for preventing phototoxicity in adults with EPP. This unit maps that regulatory status, the orphan-drug pathway behind it, and the gray-market legality question for cosmetic use.
It closes with what is coming next, including an oral MC1R agonist that could remove the implant procedure entirely, while keeping the EPP-only scope of today's approvals firmly in view.